drugset / Trial / NCT06679101
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.
Timeline
- Start
- 2024-12-16
- Primary completion
- 2031-04-28
- Completion
- 2031-04-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | — | — |
| Comparator | Daratumumab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Lenalidomide | Other / unclassified | — | — |